Home       Market Dynamics     Sector Analysis     Company Insights     AI Investing     Strategies     Contact Us     Login             

ABBVIE INC (ABBV) Stock Price Prediction and News Highlight
Tue. Nov 18, 2025

AbbVie is making significant strides in product/service development, highlighted by the successful launch of innovative products like Skyrizi, Rinvoq, and EPKINLY, which emphasize their commitment to addressing complex health conditions. Their active participation in healthcare symposiums further reinforces their role as a leader in healthcare innovation. However, the emergence of new competitors in the aesthetic treatment market poses challenges that may affect their future offerings. Overall, continued focus on innovative therapies and health advocacy can drive sustained revenue growth.

The price action of ABBVIE INC (ABBV) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.2 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for ABBV since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.3, and the negative at -0.1 on 2025-11-18. The forces of and Valuation Sentiment (-0.5) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (1.8) will drive up the price.

The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band.

Earning Release: 2025-10-31 06:30, EPS: $1.32, P/E: 177.15

ABBV
DateAttentionPricePrice
Level
ChangeSMA10
Trend
Trend
Sentiment
Hourly
Trend
Hourly
StdDev
Market
Sentiment
ActionPFund.News
Sentiment
2025-11-180%(0%)    0    0%    0.2          1.8    -1   
2025-11-170%(0%)    0    0%    0.3          1.2    -1   
2025-11-160%(0%)    0    0%    0.2          1.1    -1   
2025-11-150%(0%)    0    0%    0.6          1.5    -1   
2025-11-140%(0%)    0    0%    0.7          1.2    -7   
2025-11-130%(0%)    0    0%    1          2.3    -1   
2025-11-120%(0%)    0    0%    1          2.4    6   
2025-11-110%(0%)    0    0%    1          2.3    -1   
2025-11-100%(0%)    0    0%    0.9          2.8    -1   
2025-11-090%(0%)    0    0%    1          3.6    -1   
 
Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position.
Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force.

2025-11-18 17:03:15 The rising sales from AbbVie's therapeutic offerings, such as Botox and migraine treatments, point to a broader trend of financial growth in the biotech industry.
2025-11-18 17:03:15 The unique offering of EPKINLY gives AbbVie a competitive edge in the oncology market, particularly in addressing relapsed cases of lymphoma.
2025-11-18 17:03:15 The introduction of EPKINLY as the first bispecific combination therapy showcases a novel approach in treating complex conditions like follicular lymphoma.
2025-11-18 17:03:15 AbbVie's strong performance in Q3 is largely attributed to the success of its neuroscience-based products, indicating a fruitful sector for the company.
2025-11-18 17:03:15 The approval of EPKINLY for treating relapsed or refractory follicular lymphoma highlights the positive impact of regulatory milestones on the availability of innovative therapies.


About   Contact Us  
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA